Hikma Pharmaceuticals Stock Rating Reaffirmed by UBS AG (HIK)
Hikma Pharmaceuticals (LON:HIK)‘s stock had its “neutral” rating reiterated by investment analysts at UBS AG in a note issued to investors on Thursday, AR Network reports. They currently have a GBX 1,050 ($16.35) price objective on the stock. UBS AG’s price target indicates a potential downside of 2.51% from the stock’s previous close.
Hikma Pharmaceuticals (LON:HIK) traded down 1.64% on Thursday, hitting GBX 1077.00. The stock had a trading volume of 255,329 shares. Hikma Pharmaceuticals has a one year low of GBX 706.50 and a one year high of GBX 1128.00. The stock’s 50-day moving average is GBX 1085. and its 200-day moving average is GBX 990.8. The company’s market cap is £2.119 billion.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note to investors on Wednesday, August 21st. They now have a GBX 1,175 ($18.30) price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note to investors on Wednesday, August 21st. They now have a GBX 1,250 ($19.47) price target on the stock, up previously from GBX 1,200 ($18.69). Finally, analysts at Panmure Gordon raised their price target on shares of Hikma Pharmaceuticals from GBX 1,200 ($18.69) to GBX 1,300 ($20.25) in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock.
Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of GBX 1,133.96 ($17.66).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.